Through partnerships, CancerIQ tries to reduce barriers for patients to use genetic services to detect cancer early, said Feyi Olopade Ayodele, MBA, chief executive officer at CancerIQ.
Through partnerships, CancerIQ tries to reduce barriers for patients to use genetic services to detect cancer early, said Feyi Olopade Ayodele, MBA, chief executive officer at CancerIQ.
Transcript
What strategies are being used to inform patients about the benefits of using genetic services for early cancer detection?
The strategies that we use to educate patients on the benefits and the risks of genetic testing is really by using the channels that they really know and trust and believe in — the provider. As part of our partnership with our clients, we’re not only just dropping off software, but we’re helping them with communication strategies on how to explain this in as simple a way as possible to their patients, because there’s a lot of information on the internet and on the web and all these “less trustworthy” places. And most patients really expect their provider to know something about it. With CancerIQ we’re really helping the providers with their messaging, their mid-level staff with their messaging, and even a mammo-tech in a breast center – making sure that their messaging is clear and consistent for patients.
What barriers still exist to reaching these patients?
I’d say the barriers that still exist to reaching patients are really just the amount of time it may take a provider to incorporate genetics into their visit. What we find is a huge patient barrier is when the provider knows the patient’s at risk, knows they need a genetic evaluation, but still refers that patient outside to call a number and maybe find a genetic counsellor outside of the practice. I think what happens in that scenario is that the patient needs to make another appointment, they need to pay for parking again, they need to take time off of work, and they need to do it for a preventive service that they can’t feel, which really is a huge barrier to patient access. So what we ultimately try and do is make sure that we bring those genetic evaluation services in-house and into the practice so that there are fewer hoops that a patient needs to go through to actually access it.
IQVIA Report Spotlights Shortages for Pain, Obesity, and Oncology Therapies
November 21st 2023A new report from IQVIA provides an overview of current US drug shortages, shedding light on major areas of concern, such as medications to address pain, cardiovascular conditions, obesity and diabetes, and multiple forms of cancer.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Recent T1D Research Contradicts Common Assumptions About Patients
November 15th 2023Michael Fang, PhD, researcher and assistant professor in the division of Cardiovascular and Clinical Epidemiology at Johns Hopkins University, discussed recent findings in the type 1 diabetes (T1D) space that may alter the way providers address diabetes diagnoses.
Read More